<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386319</url>
  </required_header>
  <id_info>
    <org_study_id>Melatonin1234</org_study_id>
    <nct_id>NCT02386319</nct_id>
  </id_info>
  <brief_title>Anxiolytic and Analgesic Effects of Melatonin</brief_title>
  <acronym>ANAN-Melatonin</acronym>
  <official_title>Anxiolytic and Analgesic Effects of Melatonin: A Randomized, Double-blinded, Placebo-controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's main objective is to investigate melatonin's anxiolytic and sleep-regulating&#xD;
      effects in patients undergoing surgery. Moreover, the investigators intend to investigate the&#xD;
      pharmacokinetic parameters of melatonin in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is separated into two parts. In the first part the patients are undergoing cosmetic&#xD;
      breast surgery, and in the second part the patient undergo inguinal og umbilical surgery.&#xD;
&#xD;
      The first part is a cohort at 12 patients undergoing breast surgery. All patients in this&#xD;
      group will be treated with melatonin, and the investigators intend to investigate the&#xD;
      pharmacokinetic parameters of melatonin. Melatonin will be administrated 60 min. before&#xD;
      surgery and the evening after surgery at 9 pm.&#xD;
&#xD;
      All patients will receive an intravenous catheter. The intravenous catheter will be used for&#xD;
      blood sampling. A baseline blood sample will be taken 65 min before surgery (baseline) and&#xD;
      thereafter blood samples will be obtained 0 min., 15 min., 30 min., 45 min., 60 min., 90&#xD;
      min., 120 min., 180 min., 240 min., 300 min., 360 min. and 420 min. after administration of&#xD;
      melatonin. Blood samples will be obtained again after administration of melatonin at 9 pm. in&#xD;
      the evening in the same manner as described above. Plasma samples will be stored at minus 80&#xD;
      C and analyzed at the research laboratory of the Department of surgery, Herlev Hospital. The&#xD;
      analysis will be preformed with the RIA-technique.&#xD;
&#xD;
      The second part is a randomized, double-blind, placebo-controlled study with a total of 32&#xD;
      participants divided into a intervention group (16) and a placebo group (16). In this part&#xD;
      the investigators intend to investigate the anxiolytic and sleep-promoting effects of&#xD;
      melatonin. Melatonin and placebo will be administrated at 9 pm. the evening before surgery,&#xD;
      120 min. before surgery, immediately after surgery in the PACU and at 9 pm the evening after&#xD;
      surgery.&#xD;
&#xD;
      Anxiety will be measured by the State-Trait Anxiety Inventory (STAI) and a VAS-scale (0 mm =&#xD;
      no anxiety and 100 mm = worst anxiety). Quality of sleep will be measured at the VAS-scale as&#xD;
      well (0 mm = best sleep and 100 = worst sleep).&#xD;
&#xD;
      Randomization will be performed by a computer at randomization.com. The &quot;first generator&quot;&#xD;
      function is used. The randomization will be preformed in blocks of 4 patients in each.&#xD;
&#xD;
      Manufacturing of medications and randomization will be made by an independent pharmacist.&#xD;
&#xD;
      The primary outcome is preoperative anxiety as measured on the STAI. A previous study&#xD;
      investigated preoperative anxiety before hernia surgery and found a mean of 35.4 (SD 10.0) on&#xD;
      the STAI scale. There does not exist any generally accepted measure of how large a change on&#xD;
      the STAI scale constitutes a clinically important difference. However, a change equal to one&#xD;
      standard deviation has been suggested. In the present study, this corresponds to a minimal&#xD;
      relevant difference (MIREDIF) of 10 points on the STAI scale or 28%. A power of 80% was&#xD;
      defined, a significance level of 5% and a minimal relevant difference (MIREDIF) of 28%. From&#xD;
      these assumptions, 16 patients in each treatment group is needed&#xD;
&#xD;
      Statistics Anxiety and sleep quality will be compared at individual timepoints between groups&#xD;
      Comparison will be performed either by Mann-whitheys-test or unpaired t-test, depending on&#xD;
      the distribution of data. Values are considered significant at a p-value at 5% or less. Data&#xD;
      will be reported as mean (SD) or median (IQR) depending on the distribution of data.&#xD;
&#xD;
      Data for the blood samples will be presented as AUC plasma concentrations, half-life, maximum&#xD;
      concentration and time to maximum concentration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preoperative Anxiety</measure>
    <time_frame>60 minutes preoperative</time_frame>
    <description>The &quot;State&quot; scale of the State-Trait Anxiety Inventory (STAI). Construct: Current level of anxiety. Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Anxiety</measure>
    <time_frame>at the preoperative interview, 60 minutes prior to surgery and 4 hours postoperatively.</time_frame>
    <description>State-Trait Anxiety Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Postoperative Anxiety</measure>
    <time_frame>at the preoperative interview, 60 minutes prior to surgery, 1 and 4 hours postoperatively.</time_frame>
    <description>Visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Requirement of Remifentanil</measure>
    <time_frame>intraopeative</time_frame>
    <description>Âµg/kg/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Requirement of Propofol</measure>
    <time_frame>intraoperative</time_frame>
    <description>mg/kg/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue-opioids in the PACU</measure>
    <time_frame>0-24 hours postoperative</time_frame>
    <description>dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue-opioids in the Ward</measure>
    <time_frame>0-24 hours postoperative</time_frame>
    <description>dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Sleep Quality</measure>
    <time_frame>24 hours</time_frame>
    <description>Visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Well-being and Fatigue</measure>
    <time_frame>24 hours</time_frame>
    <description>Visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Melatonin</measure>
    <time_frame>baseline, 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, 360 min and 420 min. after melatonin administration.</time_frame>
    <description>pg/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.&#xD;
Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Gelatin capsules</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria part one:&#xD;
&#xD;
          -  Patients who are candidates for breast surgery.&#xD;
&#xD;
          -  BMI between 18 and 30&#xD;
&#xD;
          -  Visible veins in the elbow region&#xD;
&#xD;
          -  Fertile women use anti-contraception and have performed a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria part one:&#xD;
&#xD;
          -  Patients, who use daily opioids, benzodiazepines or melatonin&#xD;
&#xD;
          -  Patients diagnosed with a psychiatric disorder (defined as in medical treatment)&#xD;
&#xD;
          -  Patients with severe physical disease (ASA 3-4)&#xD;
&#xD;
          -  Patients with previous or ongoing alcohol or drug abuse&#xD;
&#xD;
          -  Patients with liver disease (defined as in medical treatment)&#xD;
&#xD;
          -  Patients diagnosed sleep disturbances&#xD;
&#xD;
          -  Patients who are unable to cooperate according to the protocol&#xD;
&#xD;
          -  Patients with allergy to melatonin&#xD;
&#xD;
        Inclusion Criteria part two:&#xD;
&#xD;
        - Male patients who are candidates for inguinal or umbilical hernia reapir&#xD;
&#xD;
        Exclusion Criteria part two:&#xD;
&#xD;
          -  Patients, who use daily opioids, benzodiazepines or melatonin&#xD;
&#xD;
          -  Patients diagnosed with a psychiatric disorder (defined as in medical treatment)&#xD;
&#xD;
          -  Patients with severe physical disease (ASA 3-4)&#xD;
&#xD;
          -  Patients with previous or ongoing alcohol or drug abuse&#xD;
&#xD;
          -  Patients with liver disease (defined as in medical treatment)&#xD;
&#xD;
          -  Patients diagnosed sleep disturbances&#xD;
&#xD;
          -  Patients who are unable to cooperate according to the protocol&#xD;
&#xD;
          -  Patients with allergy to melatonin&#xD;
&#xD;
        Withdrawal- and drop-out criteria part 2:&#xD;
&#xD;
          -  Patients can withdraw at any time during trial&#xD;
&#xD;
          -  Complications during surgery occur that lead to:&#xD;
&#xD;
               1. Immediate reoperation&#xD;
&#xD;
               2. Hospitalization to intensive care unit&#xD;
&#xD;
          -  If it is considered in the best interest of the patients physical- and psychological&#xD;
             health to withdraw from the trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis B Zetner, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital, Herlev Ringvej 75, Herlev, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <results_first_submitted>June 29, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Dennis Bregner Zetner</investigator_full_name>
    <investigator_title>MD Ph d fellow</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Surgery</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Anxiolytic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02386319/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.&#xD;
Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Melatonin: Gelatin capsules</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Placebo: Placebo capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.&#xD;
Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Melatonin: Gelatin capsules</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Placebo: Placebo capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="45" upper_limit="62"/>
                    <measurement group_id="B2" value="60" lower_limit="50" upper_limit="69"/>
                    <measurement group_id="B3" value="59" lower_limit="48" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hernia (inguinal/umbilical)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Inguinal hernia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Umbilical hernia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery (laparoscopic/open)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Laparoscopic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Open</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline State anxiety (at enrolment)</title>
          <description>The &quot;State&quot; scale of the State-Trait Anxiety Inventory (STAI). Construct: Current level of anxiety. Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="22" upper_limit="34"/>
                    <measurement group_id="B2" value="27" lower_limit="23" upper_limit="31"/>
                    <measurement group_id="B3" value="27" lower_limit="22" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Trait anxiety (at enrolment)</title>
          <description>The &quot;Trait&quot; scale of the State-Trait Anxiety Inventory (STAI). Construct: Inherent level of anxiety. Scale range: 20-40 (higher scores indicate higher level of inherent anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="23" upper_limit="34"/>
                    <measurement group_id="B2" value="27" lower_limit="24" upper_limit="30"/>
                    <measurement group_id="B3" value="29" lower_limit="23" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline VAS anxiety</title>
          <description>Visual analogue scale of anxiety. Construct: Current level of anxiety. Scale range: 1-10 (higher scores indicate higher level of current anxiety)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="B2" value="5" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="B3" value="5" lower_limit="1" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preoperative Anxiety</title>
        <description>The &quot;State&quot; scale of the State-Trait Anxiety Inventory (STAI). Construct: Current level of anxiety. Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).</description>
        <time_frame>60 minutes preoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.&#xD;
Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Melatonin: Gelatin capsules</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Placebo: Placebo capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Preoperative Anxiety</title>
          <description>The &quot;State&quot; scale of the State-Trait Anxiety Inventory (STAI). Construct: Current level of anxiety. Scale range: 20-40 (higher scores indicate higher level of current anxiety) Scores are calculated according to the STAI scoring manual by adding point from each item (possible point for each item is 1-4).</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="24" upper_limit="34"/>
                    <measurement group_id="O2" value="28" lower_limit="24" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Anxiety</title>
        <description>State-Trait Anxiety Index</description>
        <time_frame>at the preoperative interview, 60 minutes prior to surgery and 4 hours postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Postoperative Anxiety</title>
        <description>Visual analog scale</description>
        <time_frame>at the preoperative interview, 60 minutes prior to surgery, 1 and 4 hours postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Requirement of Remifentanil</title>
        <description>Âµg/kg/min</description>
        <time_frame>intraopeative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Requirement of Propofol</title>
        <description>mg/kg/min</description>
        <time_frame>intraoperative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue-opioids in the PACU</title>
        <description>dose</description>
        <time_frame>0-24 hours postoperative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue-opioids in the Ward</title>
        <description>dose</description>
        <time_frame>0-24 hours postoperative</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perioperative Sleep Quality</title>
        <description>Visual analog scale</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General Well-being and Fatigue</title>
        <description>Visual analog scale</description>
        <time_frame>24 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentrations of Melatonin</title>
        <description>pg/ml</description>
        <time_frame>baseline, 0 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, 240 min, 300 min, 360 min and 420 min. after melatonin administration.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.&#xD;
Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Melatonin: Gelatin capsules</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.&#xD;
Placebo: Placebo capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anders Gram-Hanssen</name_or_title>
      <organization>Herlev Hospital</organization>
      <phone>004526225318</phone>
      <email>anders.gram-hanssen@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

